ACOR Acorda Therapeutics Inc.

12.93
-0.45  -3%
Previous Close 13.38
Open 13.18
Price To Book 1.03
Market Cap 614929323
Shares 47,558,339
Volume 1,206,499
Short Ratio
Av. Daily Volume 948,598

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Ampyra
Improve walking in patients with multiple sclerosis
Phase 1 complete. Noted November 2017 that it will not advance into a Phase 2 study by the end of 2017, as previously expected. Evaluating next steps.
CVT-427
Migraine
Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Tozadenant
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Dalfampridine
Post stroke deficits
FDA Approval announced December 22, 2018.
INBRIJA (CVT-301)
OFF episodes of Parkinson’s disease (PD)
Phase 2 interim data were slated for 3Q 2018 - no update given to date from company.
BTT1023
Primary Sclerosing Cholangitis

Latest News

  1. Acorda Therapeutics to Present at Leerink Global Healthcare Conference
  2. Edited Transcript of ACOR earnings conference call or presentation 14-Feb-19 9:30pm GMT
  3. Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates
  4. Acorda Therapeutics (ACOR) Q4 2018 Earnings Conference Call Transcript
  5. Acorda Therapeutics (ACOR) Tops Q4 Earnings and Revenue Estimates
  6. Acorda: 4Q Earnings Snapshot
  7. Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2018
  8. The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial
  9. See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
  10. Array BioPharma (ARRY) Soars: Stock Adds 11% in Session
  11. Acorda Appoints Peter S. Carbone Senior Vice President, Quality
  12. Factors of Influence in 2019, Key Indicators and Opportunity within Rexnord, Carlisle Companies, Acorda Therapeutics, Valmont Industries, Reliance Steel & Aluminum, and Thermo Fisher Scientific — New Research Emphasizes Economic Growth
  13. Acorda Fourth Quarter/Year End 2018 Update Webcast/Conference Call Scheduled for February 14, 2019
  14. Is Acorda Therapeutics (ACOR) Stock Outpacing Its Medical Peers This Year?
  15. Have Insiders Been Selling Acorda Therapeutics, Inc. (NASDAQ:ACOR) Shares?
  16. Vertex Terminates COO Ian Smith on Code of Conduct Violation
  17. Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids
  18. Aerpio (ARPO) Jumps: Stock Rises 7.8%
  19. Acorda Announces The Lancet Neurology Publication of Phase 3 Data for INBRIJA™ (levodopa inhalation powder)